Related Experiment Video

Updated: Jul 19, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Small molecule inhibitors of protein kinases in cancer- how to overcome resistance

R Griffith1, M N Brown, A McCluskey

  • 1School of Environmental and Life Sciences, Faculty of Science and IT, University of Newcastle, Callaghan NSW 2308, Australia. renate.griffith@newcastle.edu.au

Mini Reviews in Medicinal Chemistry
|November 1, 2006
PubMed

Insights

Small molecule kinase inhibitors are promising cancer drugs, but resistance is a challenge. Targeting active kinase conformations offers a potential solution to overcome drug resistance in cancer therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Small molecule kinase inhibitors are vital anti-cancer therapeutics.
  • De novo and acquired resistance limit the efficacy of these drugs.
  • Receptor tyrosine kinases like KIT are key targets in cancer treatment.

Purpose of the Study:

  • To review the challenges of resistance to small molecule kinase inhibitors.
  • To illustrate resistance mechanisms using the KIT receptor tyrosine kinase as a model.
  • To present emerging strategies for overcoming drug resistance.

Main Methods:

  • Literature review of resistance mechanisms in kinase inhibitor therapy.
  • Case study analysis focusing on the KIT receptor tyrosine kinase.
  • Exploration of novel therapeutic approaches targeting kinase conformations.

Main Results:

  • Resistance to kinase inhibitors can be de novo or acquired.
  • Specific resistance mutations in KIT can be identified.
  • Targeting active kinase conformations shows potential to circumvent resistance.

Conclusions:

  • Drug resistance remains a significant hurdle in kinase inhibitor therapy.
  • Understanding resistance mechanisms is crucial for developing effective treatments.
  • Novel strategies like targeting active kinase conformations offer hope for improved cancer therapy.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: